Researchers found that their advanced machine learning model consistently outperformed current risk stratification techniques.

The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR. 

Advanced imaging may be able to help certain heart patients avoid the risks and discomfort associated with right heart catheterizations.

The University of Missouri Research Reactor will play a key role in the trial, as it is the only domestic producer of Y-90.

Imaging findings pertaining to the size of and blood flowing to the choroid plexus may be a common denominator between the two conditions.

Grants from $50,000 to $750,000 will be awarded to pay for physician-led studies focused on PE care.

The duo plan to establish a global center of excellence in theranostics, taking advantage of Siemens’ state-of-the-art technology and software to advance the use of radiopharmaceuticals in cancer care.

The Impella CP heart pump is being used more and more to treat cardiogenic shock, and the benefits are clear. For many older patients, however, the technology seem to fall short.